Truist upgrades Arrow Electronics stock rating on valuation By Investing.com

Truist Securities upgraded Arrow Electronics to Buy from Hold and raised its price target to $183 from $148, implying about 16% upside from the current $158 price. The firm also lifted its 2027 EPS estimate to $18.30 from $15.54, above the $14.96 consensus, citing a cheap valuation with a 14.44x P/E and 0.28 PEG. Arrow’s recent Q4 results further supported the case, with EPS of $4.39 versus $3.56 expected and revenue of $8.75B versus $8.15B forecast.

Analysis

The upgrade matters less as a call on one distributor and more as a signal that sell-side and buy-side are beginning to underwrite a normalizing earnings power well beyond the next quarter. If consensus starts to re-rate Arrow on mid-cycle earnings rather than trough multiples, the bigger second-order winner is not the stock itself but the adjacent ecosystem: component suppliers, value-added resellers, and even leveraged small-cap distributors whose balance sheets amplify any recovery in working-capital turns. The market is still pricing the group like a secularly challenged low-growth basket, so any evidence of stabilization in orders or inventory digestion can force a fast multiple catch-up.

The key setup is that estimate revisions are doing more work than the headline price target. Raising outer-year EPS materially above consensus gives institutions permission to move from “cheap for a reason” to “cheap versus revised power,” which can support several months of under-owned re-risking if margins merely avoid contraction. That said, this is a classic false-start tape: if end-demand weakens again, the market will quickly dismiss the rerating as another cyclical head fake, especially because distributors typically lose multiple support first when growth expectations roll over.

The contrarian angle is that the market may be underestimating operating leverage from even modest improvement in utilization and inventory normalization, not top-line acceleration. In that scenario, Arrow’s earnings can inflect faster than revenue because mix, turns, and procurement efficiency matter more than headline sales growth. The real risk is that the thesis depends on a gradual recovery over 2-4 quarters; any macro shock that delays customer capex or reintroduces inventory caution would compress both the estimate and the multiple at the same time.

Key Decisions for Investors

• Long ARW into the next 1-2 quarters on valuation + estimate revision momentum; target a re-rating toward 16-18x forward earnings if revisions continue, with downside limited by already depressed sentiment but vulnerable if end-demand rolls over.
• Pair long ARW vs short a higher-quality industrial/technology cyclically exposed peer basket over 3-6 months to isolate cyclical re-rating from beta; thesis is Arrow has more room for multiple expansion from a lower starting point.
• Use call spreads in ARW for a 3-6 month window rather than outright stock if you want convexity around further analyst revision waves; best risk/reward if the market starts pricing the 2027 EPS bridge earlier.
• Fade the move if ARW fails to hold post-upgrade gains for 2-3 sessions or if next channel checks show weaker bookings; the stock can retrace quickly if the market decides the EPS uplift is too far in the future.